Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
about
PARPs and the DNA damage responseUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicPoly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Mutational landscape of candidate genes in familial prostate cancerNiraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.Synthetic lethality: general principles, utility and detection using genetic screens in human cellsTargeting poly(ADP-ribose) polymerase activity for cancer therapy.Small molecule inhibitors of DNA repair nuclease activities of APE1.Medical therapy of gliomas.Cochinchina momordica seed extract induces apoptosis and cell cycle arrest in human gastric cancer cells via PARP and p53 signal pathways.Requirement for NBS1 in the S phase checkpoint response to DNA methylation combined with PARP inhibition.An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directionsPoly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancersPARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1.The ups and downs of DNA repair biomarkers for PARP inhibitor therapiesRandomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian CancerTherapeutic advances in women's cancersEvaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer populationGenomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.Consequence of the tumor-associated conversion to cyclin D1bIncreased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts.Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature.5-aza-2'-deoxycytidine-induced genome rearrangements are mediated by DNMT1.Transcriptional profiling reveals elevated Sox2 in DNA polymerase ß null mouse embryonic fibroblasts.Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancerModulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver.Sensitization strategies in lung cancerOlaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse.The DNA damage response: Balancing the scale between cancer and ageing.Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.Tumour-associated antigens: considerations for their use in tumour immunotherapy.Checkpoint kinase inhibitors: a patent review (2009 - 2010).The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.Therapeutic potential of PARP inhibitors for metastatic breast cancer.Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.Genomics and pharmacogenomics of pancreatic adenocarcinoma.Appraising iniparib, the PARP inhibitor that never was--what must we learn?Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
P2860
Q26859010-290C2A59-E41D-4141-8923-BF2EB7B5D8A2Q28071541-3EB865BE-98C6-4B06-87E7-612FC3837E18Q33851843-A7505B64-8016-4AA3-B812-3DF3822EA2C0Q34079517-1EFB990F-7CD4-4DBA-BAC1-24FC7AA3DF44Q34104143-AE9B7264-B9E3-40C9-9316-964EB804B2CBQ34151015-810D8336-7CE8-4629-B4A5-06EB5170ADCDQ34204660-330AABE7-BEE4-4D47-BC7D-48681DBE3105Q34208966-D9F82151-1FC2-4BEF-A2E8-8C22949B346BQ34218761-04081717-0D7A-4A86-95C0-F73661324258Q34423766-EFDD107A-FB67-4D20-BC3C-503E84250705Q34632186-F47342F8-33F2-4F5C-B0A1-BCB52FD3D5C2Q34632472-9B2230CF-A164-4EA6-8C37-6024E8805CE5Q34982593-BC126137-B288-47E7-B580-93CF0A5775CCQ35014762-46F9150B-AF59-4D7D-85AF-336BEA0AFAC9Q35186284-84413D3B-13E0-4C13-82FA-0D4F567D7C2CQ35232277-08FD9C2B-A5DE-482E-A83D-9E2CD0B9D30AQ35251489-925C1436-1F54-4F2C-99B1-A9FDAC71CEADQ35418973-D0F170FA-7715-4EBC-A125-4036799DDC62Q35477949-33D7671F-6EF6-49B0-9350-1FEC51E6746AQ35671422-3D7F187C-2F7A-48AE-A8E7-CEC639B14F3CQ35822584-191A9725-E16C-4155-A83E-5D6893C52D3BQ35840328-C3B24964-C812-4576-B9FA-E2FD65723FABQ35909678-2CB191C1-9D1E-4892-BAC8-BD0CAC636D8AQ35976084-F92477CE-FC68-47EF-BBED-6FCB9C9090B9Q36052193-ECE669E2-B13D-4534-B5A5-8925581F454FQ36439915-E3A42923-0D60-4142-9187-A40F3E9B3EE4Q36880037-F7D95C4B-6B76-4365-B5F9-4FAFE2478C21Q37174451-73980619-719F-48BB-8317-5D9B8F35577CQ37407122-C110A348-644A-42B4-997B-C50E70525B61Q37471094-4BC6A929-6712-4B85-B0BE-B65DBBB67454Q37824549-8A7C4A04-94D9-4709-8CDA-209AD83D5F2EQ37826009-AF6712C4-4124-4953-BE07-908FFDDF770CQ37848203-19D12CE0-6E4E-48BD-85E6-E0DA1BF68304Q37877694-78698505-20ED-4BF2-B86A-D5D0C4856889Q37925127-B9B97B53-DA85-4A38-897B-F31516DE1B9FQ37931893-EE166E12-F173-4BDA-BD2E-8A28AFDBE047Q37968253-1A7BE700-D60E-4C05-A569-FE90C77B1DB0Q37970279-E5DBF159-A3DF-4391-B5FE-0D25779B5E50Q38152942-819DFB2E-8765-425D-B3BA-B31204113914Q38644956-C291E6A2-F44A-4D4C-9407-D36DABE0639E
P2860
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
@en
type
label
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
@en
prefLabel
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
@en
P1476
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective
@en
P2093
Johann S de Bono
Timothy A Yap
P356
10.1016/J.EJCA.2009.10.021
P577
2010-01-01T00:00:00Z